Inventaire - i tuoi amici e le tue comunità sono la tua biblioteca

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.

pubblicato in: Pharmacogenomics

data di pubblicazione: 2012-07-01

argomento principale: tumore del pancreas

Cita articoli 29

Data

Titolo

Autori

2011-10-25

Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy

Elisa Giovannetti, Niccola Funel, Maurizio Lucchesi
2010-08-01

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms
2010-11-01

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer

James Lewis Abbruzzese, Donghui Li, Milind Javle, Motofumi Tanaka, Xiaoqun Dong, Cathy Eng
2009-01-01

Clinical pharmacology and pharmacogenetics of gemcitabine

Federico Innocenti
2009-12-22

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity

James Lewis Abbruzzese, Donghui Li, Milind Javle, Motofumi Tanaka
2009-04-15

Generating genome-scale candidate gene lists for pharmacogenomics

Søren Brunak
2008-06-12

Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics

Richard Weinshilboum, Irene Moon, Linda Pelleymounter, Pinar Aksoy, Bruce W Eckloff, Eric D Wieben, Vivien C Yee, Oreste Ezequel Salavaggione
2008-09-01

Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression

Anthony Batzler, Michelle Hildebrandt, Brooke L Fridley, Stephanie L Safgren
2008-06-05

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients

Richie Soong
2008-02-12

ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study

Tian-Lu Cheng
2008-04-01

Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine

Sevtap Savas, Sukru Tuzmen, Noel Pabalan, Hamdi Jarjanazi
2007-01-16

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

Yusuke Mizukami, Toshikatsu Okumura
2006-04-01

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine

Elisa Giovannetti, Niccola Funel, Generoso Bevilacqua, Romano Danesi
2006-01-31

Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter
2005-03-01

Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene

Stephen A. Baldwin
2005-07-01

Mammalian Groucho homologs: redundancy or specificity?
2004-01-01

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway
2004-09-01

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer
2004-11-01

Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients
2004-10-01

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma

Charles Dumontet, John R. Mackey
2003-10-01

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine
2003-05-01

Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1

Thomas E. Ferrin
2002-02-01

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
2002-06-01

Genetic association studies: design, analysis and interpretation

Cathryn Lewis
2000-10-01

Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs

Giuseppe Giaccone
2000-02-02

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
1999-11-01

Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.
1999-06-25

Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells
1993-08-01

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

Articolo - wd:Q54494355

Benvenuto su Inventaire

la biblioteca dei tuoi amici e della tua comunità

ulteriori informazioni